Additionally, about 30% of patients with MM harbor mutations in the mitogen-activated protein kinase (MAPK) pathway, which includes the KRAS, NRAS and BRAF genes, making it the most affected signaling pathway and, therefore, an appealing target for biomarker exploration (17). This evidence concerns the gene WNK2 and Miyoshi myopathy.